Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.41

-4.0%

12:49 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (2356)	12/20/2000 2:00:23 PM
From: Londo	Read Replies (3) of 52153

MCDE doesn't have enough cash to warrant a higher valuation.. from a 6-second scan of its website, they don't have any products, and just a ton of anti microbial research.. and given that it only has 15 million in the bank (2.2 million debt), it will need some source of cash before they manage to get something out.. do you see something I don't? As for the state of the market, lesser known biotechs which I consider "cash rich" are faring a little better.. CEGE's only down 4% despite the fact that its ABGX sister tanked about 10%.. CRA and HGSI (two other balance sheet giants) are only down because they are widely known and owned by retail shareholders, who were most likely to get margin called out of the stock..

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next